{"name": "Bellicum Pharmaceuticals",
 "permalink": "bellicum-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/bellicum-pharmaceuticals",
 "homepage_url": "http://www.bellicum.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2004,
 "founded_month": 7,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@bellicum.com",
 "phone_number": "",
 "description": "Cancer, Infectious Disease Treatment",
 "created_at": "Thu Nov 05 01:47:38 UTC 2009",
 "updated_at": "Sat Apr 06 05:11:03 UTC 2013",
 "overview": "\u003Cp\u003EBellicum Pharmaceuticals, Inc. is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum\u0026#8217;s novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response. Our lead product, BP-GMAX-CD1, is in Phase I clinical trials.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       51],
      "assets/images/resized/0006/4954/64954v1-max-150x150.png"],
     [[230,
       79],
      "assets/images/resized/0006/4954/64954v1-max-250x250.png"],
     [[230,
       79],
      "assets/images/resized/0006/4954/64954v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Founder, Executive Chairman, CMO",
    "person":
     {"first_name": "Kevin",
      "last_name": "Slawin",
      "permalink": "kevin-slawin",
      "image": null}},
   {"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Thomas",
      "last_name": "J. Farrell",
      "permalink": "thomas-j-farrell",
      "image": null}},
   {"is_past": false,
    "title": "CSO",
    "person":
     {"first_name": "David",
      "last_name": "M. Spencer",
      "permalink": "david-m-spencer",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$34M",
 "funding_rounds":
  [{"round_code": "seed",
    "source_url": "http://www.bellicum.com/images/Press-Release/bellicum%20financing%20final.pdf",
    "source_description": "BELLICUM PHARMACEUTICALS ANNOUNCES   $3.75 MILLION IN FINANCING",
    "raised_amount": 2300000.0,
    "raised_currency_code": "USD",
    "funded_year": 2007,
    "funded_month": 10,
    "funded_day": 9,
    "investments":
     []},
   {"round_code": "grant",
    "source_url": "http://www.bellicum.com/images/Press-Release/bellicum%20financing%20final.pdf",
    "source_description": "BELLICUM PHARMACEUTICALS ANNOUNCES   $3.75 MILLION IN FINANCING",
    "raised_amount": 1450000.0,
    "raised_currency_code": "USD",
    "funded_year": 2007,
    "funded_month": 10,
    "funded_day": 9,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "The Texas Emerging Technology Fund",
         "permalink": "the-texas-emerging-technology-fund",
         "image":
          {"available_sizes":
            [[[150,
               59],
              "assets/images/resized/0003/0335/30335v2-max-150x150.png"],
             [[250,
               99],
              "assets/images/resized/0003/0335/30335v2-max-250x250.png"],
             [[302,
               120],
              "assets/images/resized/0003/0335/30335v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "http://www.bellicum.com/images/Press-Release/bellicum%2010%2009%20financing%20final.pdf",
    "source_description": "BELLICUM PHARMACEUTICALS ANNOUNCES   $4.5 MILLION IN NEW FUNDING",
    "raised_amount": 4500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 11,
    "funded_day": 4,
    "investments":
     []},
   {"round_code": "unattributed",
    "source_url": "http://www.fiercebiotech.com/story/bellicum-receives-57m-funding-caspacide/2011-03-25?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Bellicum receives $5.7M in funding for CaspaCIDe",
    "raised_amount": 5700000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 3,
    "funded_day": 25,
    "investments":
     []},
   {"round_code": "b",
    "source_url": "http://www.finsmes.com/2012/03/bellicum-pharmaceuticals-raises-20m-series-financing.html?utm_source=feedburner\u0026utm_medium=feed\u0026utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29",
    "source_description": "Bellicum Pharmaceuticals Raises $20M in Series B Financing",
    "raised_amount": 20000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 3,
    "funded_day": 8,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "AVG Ventures",
         "permalink": "avg-ventures",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org": null,
       "person":
        {"first_name": "Dennis",
         "last_name": "Stone",
         "permalink": "dennis-stone",
         "image": null}},
      {"company": null,
       "financial_org":
        {"name": "Remeditex Ventures",
         "permalink": "remeditex-ventures",
         "image":
          {"available_sizes":
            [[[148,
               66],
              "assets/images/resized/0019/3757/193757v1-max-150x150.jpg"],
             [[148,
               66],
              "assets/images/resized/0019/3757/193757v1-max-250x250.jpg"],
             [[148,
               66],
              "assets/images/resized/0019/3757/193757v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org": null,
       "person":
        {"first_name": "James",
         "last_name": "Brown",
         "permalink": "james-brown",
         "image":
          {"available_sizes":
            [[[107,
               150],
              "assets/images/resized/0007/6503/76503v1-max-150x150.jpg"],
             [[130,
               182],
              "assets/images/resized/0007/6503/76503v1-max-250x250.jpg"],
             [[130,
               182],
              "assets/images/resized/0007/6503/76503v1-max-450x450.jpg"]],
           "attribution": "\u003Cp\u003Ehttp://www.infrastructsecurity.com/New-CEOs-Focus-on-Strategic-Planning-and-Growth.htm\u003C/p\u003E"}}}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Texas Life Science Plaza",
    "address2": "2130 West Holcombe Boulevard, Suite 850",
    "zip_code": "77030 ",
    "city": "Houston",
    "state_code": "TX",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        93],
       "assets/images/resized/0016/0655/160655v2-max-150x150.jpg"],
      [[250,
        156],
       "assets/images/resized/0016/0655/160655v2-max-250x250.jpg"],
      [[450,
        281],
       "assets/images/resized/0016/0655/160655v2-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}